Omics! Omics!

A computational biologist's personal views on new technologies & publications on genomics & proteomics and their impact on drug discovery

Tuesday, March 31, 2026

A Wish For Snail-Inspired Tulips

›
About a year ago we took a family vacation to the Netherlands with a prime goal to see tulips - and tulips we did see!  Even a rainy day (wh...
Monday, March 30, 2026

icon16: Precise Amplification for All!

›
I've loved the n6tec icon96 instrument since they first tipped me about it several years back.  The idea of running 96 independent PCRs ...
Sunday, March 29, 2026

Who's Going to Buy Roche Axelios?

›
After Roche's AGBT presentation, a key question for many is "who is going to buy an Axelios?".  Below are some thoughts on the...
2 comments:
Friday, March 27, 2026

LinkedIn Laments 1 of N: Where's the API?

›
In my current role I spend a lot of time on LinkedIn. A core task is to identify possible customers, and LinkedIn is rich hunting ground. I...
Monday, March 23, 2026

ElysION Fields

›
Even before new CEO Francis Van Parys took the reins at Oxford Nanopore with the start of the month, the company had made yet another primin...
2 comments:
Tuesday, March 10, 2026

Roche Axelios1 Run Pricing: Not A Knockout - Yet?

›
By far the most awaited news at AGBT was Roche's reveal of the pricing scheme for Axelios 1 consumables: what would be the structure and...
Friday, March 06, 2026

Complete Genomics Sale: Gruyère or Emmental?

›
A bit of interesting news during AGBT was the announcement of the sale of Complete Genomics to Swiss Rockets, a Basel-based company which ha...
1 comment:
Thursday, March 05, 2026

Ultima Genomics Solaris 2.0: Greater Version, Smaller Beads, Lose A Box

›
Ultima Genomics announced the 2.0 version of their Solaris chemistry at AGBT.  Perhaps the biggest splash here is that Solaris 2.0 relies on...
2 comments:
Friday, February 27, 2026

Element Previews High-Throughput VITARI

›
On the Thursday before AGBT, Element Biosciences unveiled their VITARI high throughput sequencer, expected to ship in the second half of thi...
2 comments:
Wednesday, February 25, 2026

Illumina Constellation Becomes TruPath Genome

›
Illumina is rebranding their Constellation mapped read technology to TruPath Genome and launching it into the marketplace. Priced at $395 pe...
7 comments:
Tuesday, February 24, 2026

Canal Biosciences: Ligation Libraries without Distortions from End Repair

›
Canal Biosciences is a small startup in the library prep space that is making a debut at AGBT this year as a contributing sponsor.  Based in...
3 comments:
Monday, February 23, 2026

Wish: Scientific Poster Snap Organizer App

›
AGBT is another conference with a wonderful wealth of scientific posters and never enough time to view them all properly. I definitely enjoy...
Sunday, February 22, 2026

AI Agent -Driven Biochemical Optimization

›
When I started this space, I vowed not to become just a mouthpiece of my employer - but when my employer does something interesting, of cour...
Wednesday, February 18, 2026

AGBT 2026 Preview

›
AGBT starts on Monday at the Signia by Hilton Bonnet Creek in Orlando on Monday, but the pre-conference flurry of announcements is already r...
2 comments:
Sunday, February 08, 2026

Pancreatic Adenocarcinoma Mutation Trajectories at Single Cell Resolution

›
Single cell RNA sequencing is nearly ubiquitous; single cell DNA sequencing has been much rarer.  I'm going to dive in a bit - but not a...
Monday, February 02, 2026

Non-coding DNA's Alpha Moment

›
I had been meaning to read the AlphaGenome paper on non-coding variant effect prediction from Google DeepMind which recently showed up in N...
Thursday, January 29, 2026

Sequencer vs. Library Prep Market Structures

›
Something I started pondering as I was prepping my JP Morgan items: the structure of the market for sequencing library prep is very differen...
2 comments:
Wednesday, January 28, 2026

P2 Solo: ONT Extends Support But Not Sales

›
A brief update to the earlier P2 Solo piece - Oxford Nanopore has now announced they will extend their support for the device until 2030, b...
2 comments:
Sunday, January 25, 2026

ONT Axes P2 Solo, Roiling Community

›
Oxford Nanopore has a serious case of user community unrest, triggered by the announcement that the P2 Solo (aka P2s) will be phased out sta...
2 comments:
Thursday, January 22, 2026

JP Morgan 2026 Roundup

›
The J.P. Morgan conference last week was mostly small tidbits of info on the sequencing front, with Element delivering the one big teaser an...
‹
›
Home
View web version

About Me

My photo
Keith Robison
Dr. Robison spent 10 years at Millennium Pharmaceuticals working with various genomics & proteomics technologies & working on multiple teams attempting to apply these throughout the drug discovery process. He spent 2 years at Codon Devices working on a variety of protein & metabolic engineering projects as well as monitoring a high-throughput gene synthesis facility. After a brief bit of consulting, he rejoined the cancer drug discovery field at Infinity Pharmaceuticals in May 2009. In September 2011 he joined Warp Drive Bio, a startup applying genomics to natural product drug discovery. In February 2019 he joined Ginkgo Bioworks, a synthetic biology company. Other recurring characters in this blog are his late loyal Shih Tzu Amanda, his current Shih Poo Lily and his now adult son alias TNG (The Next Generation). Dr. Robison can be reached via his Gmail account, keith.e.robison@gmail.com You can also follow him on Twitter as @OmicsOmicsBlog.
View my complete profile
Powered by Blogger.